World News
-
Sunshine Lake Pharma breaks US barriers with historic FDA approval for LANGLARA
The decision positions LANGLARA as only the fourth insulin glargine product available in the US market, joining established products commercialized by Novo Nordisk, Sanofi and Eli Lilly.
-
Merck expands HIV portfolio with FDA approval of Idvynso single-tablet regimen
The tablet combines 100 mg of doravirine and 0.25 mg of islatravir in a once-daily formulation.
-
Siemens Healthineers secures US$83M public-private funding to scale photon flash radiotherapy
Photon Flash radiotherapy delivers radiation more than 100 times faster than conventional radiotherapy techniques, to reduce damage to surrounding healthy tissue while effectively targeting tumors.
-
BeOne Medicines secures US$20M option on Huahui Health’s trispecific cancer antibody HH160
If fully developed and commercialized, Huahui Health could receive up to US$1.9 billion in milestone-based payments, in addition to tiered royalties on future global sales.
-
UCB expands autoimmune pipeline with US$2.2B Candid Therapeutics acquisition
The acquisition is expected to close by the end of the second quarter or early third quarter of 2026, pending regulatory approvals and customary closing conditions.
-
Amgen boosts US biomanufacturing with additional US$300M investment in Puerto Rico
Through this expansion, the company aims to strengthen advanced manufacturing capabilities, support workforce development, and generate hundreds of construction-related jobs.
-
Thermo Fisher Scientific to sell microbiology business to Astorg in over US$1B strategic divestment
Thermo Fisher’s microbiology unit generated US$645 million in revenue in 2025 and operates within the company’s specialty diagnostics segment.
-
Merck completes US$6.7B acquisition of Terns Pharmaceuticals to strengthen the leukemia drug pipeline
Terns has now become a wholly owned subsidiary of Merck, and its common stock has ceased trading on the Nasdaq Global Select Market.
-
WHO validates Australia as first high-income nation to eliminate trachoma
The achievement places Australia among 63 countries globally and 16 in the WHO Western Pacific Region that have eliminated at least one NTD.
-
BioMarin completes US$4.8B acquisition of Amicus Therapeutics to expand rare disease portfolio
The acquisition brings Amicus Therapeutics fully under BioMarin’s global operations, integrating its late-stage and commercial-stage rare disease assets into BioMarin’s established infrastructure.